VistaGen Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by VistaGen Therapeutics, Inc. on August 14, 2014. The report details a corporate action involving a reverse stock split effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure adjustment rather than financial performance.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-20 reverse split of its authorized, issued, and outstanding common stock.
- Fractional Shares: No fractional shares were issued; stockholders entitled to a fractional share received one whole post-split share.
- Trading Symbol: Trading on the OTCQB resumed under the symbol "VSTAD" (with a "D" suffix indicating the pending split) effective August 14, 2014.
- Future Symbol: After 20 business days, the ticker symbol will revert to "VSTA".
- CUSIP: The new CUSIP number is 92840H202.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks beyond the mechanics of the reverse split. The action was approved by the Financial Industry Regulatory Authority (FINRA) on August 13, 2014.
Investor Verification Checklist
- Verify the new share count and adjusted share price on the OTCQB under symbol "VSTAD".
- Confirm the date the ticker symbol reverts to "VSTA" (20 business days post-split).
- Review the attached Certificate of Change (Exhibit 3.1) for specific details on authorized share adjustments.
- Check the press release (Exhibit 99.1) for any additional context regarding the rationale for the split.